Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average) (2022 - 2025)

Taysha Gene Therapies' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $307.2 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 25.86% year-over-year to $307.2 million; the TTM value through Sep 2025 reached $307.2 million, up 25.86%, while the annual FY2024 figure was $250.1 million, 115.41% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $307.2 million at Taysha Gene Therapies, up from $298.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $307.2 million in Q3 2025 and bottomed at $38.2 million in Q1 2022.
  • The 4-year median for Shares Outstanding (Weighted Average) is $116.1 million (2023), against an average of $154.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 265.55% in 2024 before it increased 16.46% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $44.0 million in 2022, then surged by 164.2% to $116.1 million in 2023, then soared by 115.41% to $250.1 million in 2024, then grew by 22.8% to $307.2 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Shares Outstanding (Weighted Average) are $307.2 million (Q3 2025), $298.0 million (Q2 2025), and $269.3 million (Q1 2025).